| Статус: | Unknown status |
| Фаза: | Phase 2 |
| Начало: | 14 мая 2019 г. |
| Окончание: | 2 декабря 2023 г. |
| Описание: | This study evaluate possibility of brentuximab vedotin, administered after first treatment failure (no response or relapse after I line therapy) of Hodgkin's lymphoma, to induce durable response or cure without autologous stem cell transplantation. |
| смотреть на ClinicalTrials.gov |